CMPX vs CRIS

Compass Therapeutics, Inc. vs Curis, Inc. — Valuation Comparison 2026

CMPX

Biological Products, (No Diagnostic Substances)
Compass Therapeutics, Inc.
Quality
5.3
out of 10
Value Trap
30
LOW
Price
$2.38
Last close
Models
9/13
Active
VS

CRIS

Biological Products, (No Diagnostic Substances)
Curis, Inc.
Quality
5.0
out of 10
Value Trap
39
LOW
Price
$0.57
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CMPX Fair ValueCMPX Upside CRIS Fair ValueCRIS Upside
Bayesian DCF Intrinsic $0.66 -72.5% $0.25 -56.7%
First Chicago Scenario $0.34 -82.5% $0.33 -41.9%
ML-RIV Intrinsic $0.18 -90.4% $0.35 -40.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CMPX vs CRIS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CMPX vs CRIS — Which Stock Is More Undervalued?

CMPX scores higher with a 5.3/10 quality rating vs CRIS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Compass Therapeutics, Inc. (CMPX) and Curis, Inc. (CRIS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CMPX currently trades at $2.38 with a QOC of 5.3/10, while CRIS trades at $0.57 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).